In this study, Her2/VEGFR2/CD3 (SO) with an every-other-day treatment schedule demonstrated impressive in vivo tumor growth inhibition but no observed adverse effects, suggesting the potential combination of improved efficacy and safety intervention. This evidence concerns the gene ERBB2 and neoplasm.